関連する実験動画
Updated: Sep 8, 2025

05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.8K
ドクソルビシン後にペムブロリズマブとレンバチニブを併用した左心房機能障害: 原因は?
Yoshihide Ishikawa1, Masataka Suzuki1, Eri Konda2
1Department of Cardiology, Kobe City Nishi-Kobe Medical Center, Kobe, Japan.
JACC. Case reports
|September 5, 2025
まとめ
複数の化学療法による心臓毒性を特定することは複雑です. このケースは 免疫チェックポイント阻害剤と標的治療が 心不全を引き起こすことを示し 安全な癌治療のための多分野評価を強調しています
科学分野:
- 腫瘍学
- 心臓病科
- 薬理学について
背景:
- 組み合わせた化学療法療法はがんの治療結果を改善しますが,特定の心臓毒性物質の特定には課題があります.
- 複数の化学療法が同時に開始された場合,薬物誘発の心臓毒性の診断は複雑になります.
- 心臓毒性は,がん治療において重大な懸念事項であり,重度の心臓機能障害につながる可能性があります.
研究 の 目的:
- 複数の化学療法薬が同時に投与されたときの心臓毒性の診断における課題を強調する.
- 子宮内膜がん患者におけるペンブロリズマブ,レンバチニブ,ドクソルビシンの潜在的心臓毒性メカニズムを調査する.
- 化学療法による心臓毒性の管理における多学科協力の重要性を強調する.
主な方法:
- ドクソルビシンとペンブロリズマブとレンバチニブを併用した 58歳の子宮内膜がん患者の症例報告
- 心臓の磁気共鳴画像 (CMR) と心臓内膜生検により,心臓の機能と病理を評価する.
- ペムブロリズマブ単独治療の中止と再開後の心臓機能回復の分析
主要な成果:
- 患者の心臓機能不全は急性心筋炎によるエジェクション分数減少 (26%) であった.
- 心臓内膜生検では 筋縮症ではなく インタースティシャル線維症とTリンパ球の浸透を示した.
- ペンブロリズマブとレンバチニブを中止すると,ステロイドの使用なしに左心房機能が回復しました.
- 肺転移に対するペムブロリズマブ単独治療の再開は許容された.
結論:
- このケースは,免疫チェックポイント阻害剤誘発性心筋炎と可逆性心筋毒性を対象薬と区別する必要性を強調しています.
- ペンブロリズマブ,レンバチニブ,および以前のドクソルビシン治療による潜在的重なり心毒性が観察されました.
- 免疫チェックポイント阻害剤の再投与を検討するなど,心毒性化学療法疑惑の正確な診断と管理のために,多学科的な議論が不可欠です.
関連する概念動画
Cardiomyopathy II: Dilated Cardiomyopathy
21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Cardiomyopathy V: Interprofessional Care
30
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30
Cardiomyopathy IV: Restrictive Cardiomyopathy
25
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
25
Cardiomyopathy III: Hypertrophic Cardiomyopathy
45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
Heart Failure Drugs: Inotropic Agents
716
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
716

